Marinus Pharmaceuticals Continues Phase 3 Trial for Epilepticus Treatment Despite Setback
RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) recently announced its decision to proceed with the Phase 3 RAISE trial of intravenous (IV) ganaxolone for treating refractory status epilepticus (RSE), …
Marinus Pharmaceuticals Continues Phase 3 Trial for Epilepticus Treatment Despite Setback Read More